Overview

Sorafenib Treatment in Non-Small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor

Status:
Completed

Trial end date:
2012-04-01

Target enrollment:

Participant gender:

Summary

This trial's aim is to evaluate the efficacy and toxicity of sorafenib in relapsed advanced Non-Small Cell Lung Cancer (NSCLC) after failure of epidermal growth factor receptors-tyrosine kinase inhibitor (EGFR-TKI) treatment and to explore the correlation between clinical outcomes and biochemical modulation of signal transduction pathways.

Phase:

Phase 2

Details

Lead Sponsor:

Chinese Society of Lung Cancer

Treatments:

Mitogens
Niacinamide
Sorafenib